Incidence of skeletal morbidity rates over time in patients with multiple myeloma-related bone disease as reported in randomized trials employing bone-modifying agents

By Poon Michael   Zeng Liang   Zhang Liying   Hsiao Janey   Wong Erin   Lam Henry   Bedard Gillian   Chow Edward  

Journal of Comparative Effectiveness Research, Vol. 2, Iss. 1, 2013-01 ,pp. : 69-76

Future Medicine

Access to resources Recommend Favorite

Paraneoplastic Hyperamylasaemia in Association with Multiple Myeloma

By  

Acta Haematologica, Vol. 117, Iss. 4, 2007-01 ,pp. : 242-245

Karger

Access to resources Recommend Favorite

Racial/ethnic disparities in inflammatory gene single‐nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis

By  

CANCER, Vol. 121, Iss. 7, 2015-04 ,pp. : 1138-1146

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 2, 1998-02 ,pp. : 317-325

John Wiley & Sons Inc

Access to resources Recommend Favorite

Large-scale association study between two coding LRP5 gene polymorphisms and bone phenotypes and fractures in men

By Grundberg E.   Lau E.   Lorentzson M.   Karlsson M.   Holmberg A.   Groop L.   Mellström D.   Orwoll E.   Mallmin H.   Ohlsson C.   Ljunggren Ö.   Åkesson K.  

Osteoporosis International, Vol. 19, Iss. 6, 2008-06 ,pp. : 829-837

Springer Publishing Company

Access to resources Recommend Favorite